TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06582017: Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

Sponsor: Nammi Therapeutics Inc · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 100 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$1,382,304

Rescue Site Savings

+$911,064

Unlock Full NCT06582017 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06582017 Rescue Dossier →